Recent Blog Posts

View Post: IP Pharma Doc: Recent press releases: Brimonidine tartrate ...
12 Nov 2009 by Dr DK Sarwal  
Innovator Allergan announced (in a press release Here ) that the United States District Court for the District of Delaware has ruled in favor of Allergan on key patents covering Brimonidine tartrate ophthalmic solution 0.1% and 0.15% ...
View Blog: IP Pharma Doc - http://ippharmdoc.blogspot.com/

---

View Post: Allergan wins in Brimonidine patent infringement case ...
26 Oct 2009
... in favor of drugmaker Allergan, its patent infringement suit against Exela PharmSci and Apotex seeking to market purported generic versions of Allergan's drugs Alphagan (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. ...
View Blog: thepharmaletter.com - http://www.thepharmaletter.com/

---

View Post: Recent patent infringement cases filed in the Eastern District of ...
12 Nov 2009 by Marilyn Tennissen  
"The commercial manufacture, use, offer for sale, sale and/or importation of Alcon's proposed generic Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5% in violation of Allergan's patent rights will cause harm to ...
View Blog: Southeast Texas Record - - http://www.setexasrecord.com/

---

View Post: Patent Docs: Court Report
15 Nov 2009 by Patent Docs  
... 2008) following a Paragraph IV certification as part of Alcon's filing of an ANDA to manufacture a generic version of Allergan's Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution, used to treat glaucoma). ...
View Blog: Patent Docs - http://www.patentdocs.org/

---

View Post: Allergan Announces Victory in Brimonidine Patent Infringement Case ...
25 Oct 2009
("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, ...
View Blog: Pharmaceutical Events (November-2009) - http://www.pharmiweb.com/

---

View Post: Generic Pharmaceuticals and Patents: Allergan Announces Victory in ...
25 Oct 2009 by Amit  
... suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd., Apotex, Inc. and Apotex Corp. for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. ...
View Blog: Generic Pharmaceuticals and Patents - http://genericspatent.blogspot.com/

---

View Post: Alphagan-P (Brimonidine Tartrate) Drug Information: Uses, Side ...
3 Apr 2009
ALPHAGAN® P (brimonidine tartrate ophthalmic solution) is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. The chemical name of brimonidine tartrate is 5-bromo-6-(2-imidazolidinylideneamino) quinoxaline L-tartrate. ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: Allergan Reports Third Quarter 2009 Operating Results - Drugs.com ...
29 Oct 2009
(collectively, the "Defendants") finding that the patents are valid and enforceable against the Defendants and that the Defendants' proposed generic versions of Allergan's ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and ...
View Blog: Drugs.com - Pharma News - http://www.drugs.com/news.html

---

View Post: Allergan, Inc. Receives FDA Approval for Combigan (brimonidine ...
31 Oct 2007
Combigan is the newest addition to Allergan's comprehensive glaucoma portfolio, which also includes Lumigan (bimatoprost ophthalmic solution) 0.03% and Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. ...
View Blog: Drugs.com - New Drug Approvals - http://www.drugs.com/newdrugs.html

---

View Post: Sansrosa gel vs. eyes drops absorption trial details posted ...
16 Jun 2008 by Digital Davo  
The bit that is new in this trial is that all of the participants will have moderate to severe erythematous rosacea and use the brimonidine ophthalmic solution. The group will be split randomly such that 1/2 will use the new Sansrosa ...
View Blog: Rosacea - http://rosacea-support.org/

---